Cirrhosis: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (→Prognosis: moved content to new MELD page) |
imported>Robert Badgett (→Complications: started Hepatorenal syndrome) |
||
| Line 4: | Line 4: | ||
===Ascites=== | ===Ascites=== | ||
{{main|Ascites}} | {{main|Ascites}} | ||
===Hepatic encephalopathy=== | ===Hepatic encephalopathy=== | ||
{{main|Hepatic encephalopathy}} | {{main|Hepatic encephalopathy}} | ||
===Hepatorenal syndrome=== | |||
Octreotide/Midodrine combined therapy can help according to a [[randomized controlled trial]].<ref name="pmid17235705">{{cite journal |author=Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA |title=Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome |journal=Dig. Dis. Sci. |volume=52 |issue=3 |pages=742–8 |year=2007 |pmid=17235705 |doi=10.1007/s10620-006-9312-0 |issn=}}</ref> | |||
==Prognosis== | ==Prognosis== | ||
Revision as of 16:07, 14 January 2008
Cirrhosis is a "liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules."[1]
Complications
Ascites
Hepatic encephalopathy
Hepatorenal syndrome
Octreotide/Midodrine combined therapy can help according to a randomized controlled trial.[2]
Prognosis
MELD Score
The MELD Score can help predict mortality. An online calculator is available.
References
- ↑ Anonymous. Liver cirrhosis. National Library of Medicine. Retrieved on 2008-01-07.
- ↑ Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA (2007). "Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome". Dig. Dis. Sci. 52 (3): 742–8. DOI:10.1007/s10620-006-9312-0. PMID 17235705. Research Blogging.